Table 1.
Clinicopathological characteristics of patients
| Patient characteristics | Number of patients (n = 44) | Percentage |
|---|---|---|
| Age | ||
| ≤ 66 years | 24 | 54.5 |
| > 66 years | 20 | 45.5 |
| Sex | ||
| Male | 27 | 61.4 |
| Female | 17 | 38.6 |
| Stage | ||
| IV | 44 | 100 |
| ECOG | ||
| 0 | 12 | 27.2 |
| 1 | 23 | 52.3 |
| 2 | 8 | 18.2 |
| 3 | 1 | 2.3 |
| Primary tumor location | ||
| Body | 19 | 43.2 |
| Tail | 12 | 27.3 |
| Head | 13 | 29.5 |
| First-line treatment | ||
| Gemcitabine/ ± nab-paclitaxel | 37 | 84.1 |
| FOLFIRINOX | 4 | 9.1 |
| No treatment | 3 | 6.8 |
| Number of metastatic lesions | ||
| One | 24 | 54.6 |
| More than one | 20 | 45.4 |
| Metastatic lesions location | ||
| Hepatic | 36 | 81.8 |
| Non-hepatic | 8 | 18.2 |
| Tissue Biopsy RAS statusa | ||
| RAS mutated | 20 | 69 |
| RAS wild-type | 9 | 31 |
| Liquid Biopsy RAS status | ||
| RAS mutated | 35 | 79.5 |
| RAS wild-type | 9 | 20.5 |
aFor the analysis of RAS mutational status, primary tumor tissue was available in 65.9% (29/44) of patients